Literature DB >> 8395435

Non-insulin-like action of sodium orthovanadate in the isolated perfused liver of fed, non-diabetic rats.

M Roden1, K Liener, C Fürnsinn, M Prskavec, P Nowotny, I Steffan, H Vierhapper, W Waldhäusl.   

Abstract

Vanadium compounds exert insulin-like effects on isolated rat adipocytes and skeletal muscle and improve glucose homeostasis in diabetic rats and mice. However, reports on metabolic actions of vanadium in the liver are still contradictory. Thus, the acute effect of sodium orthovanadate infusion on net glucose production was measured in isolated perfused livers of non-fasting, non-diabetic rats. Continuous infusion (0.2 ml/min; 90 min) of vanadate (10-500 mumol/l) rapidly increased hepatic glucose (p < 0.001), but not cyclic AMP output, reaching peak values after 20 min. The cumulative glucose release displayed concentration dependence with a maximal net effect of 394.3 mumol/100 g body weight and an apparent half-maximal effective vanadate concentration of 19.6 mumol/l. The glycogenolytic response to vanadate was almost completely blocked by 100 mU/l insulin (p < 0.005), by 0.1 mmol/l indomethacin (p < 0.05) and in the absence of Ca2+ (p < 0.001). These results indicate that sodium orthovanadate stimulates glycogenolysis in livers of fed, non-diabetic rats by a Ca(2+)-dependent mechanism, which may involve the release of prostaglandins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395435     DOI: 10.1007/bf00404068

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  39 in total

1.  Glycogenolytic, noninsulin-like effects of vanadate on rat hepatocyte glycogen synthase and phosphorylase.

Authors:  F Bosch; J Ariño; A M Gómez-Foix; J J Guinovart
Journal:  J Biol Chem       Date:  1987-01-05       Impact factor: 5.157

2.  Effects of vanadium on glucose metabolism in vitro.

Authors:  E L Tolman; E Barris; M Burns; A Pansini; R Partridge
Journal:  Life Sci       Date:  1979-09-24       Impact factor: 5.037

3.  Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate.

Authors:  S M Brichard; C J Bailey; J C Henquin
Journal:  Diabetes       Date:  1990-11       Impact factor: 9.461

4.  Selectivity of the insulin-like actions of vanadate on glucose and protein metabolism in skeletal muscle.

Authors:  A S Clark; J M Fagan; W E Mitch
Journal:  Biochem J       Date:  1985-11-15       Impact factor: 3.857

5.  Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle.

Authors:  L Rossetti; M R Lauglin
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

6.  Vanadate treatment of streptozotocin diabetic rats restores expression of the insulin-responsive glucose transporter in skeletal muscle.

Authors:  H V Strout; P P Vicario; C Biswas; R Saperstein; E J Brady; P F Pilch; J Berger
Journal:  Endocrinology       Date:  1990-05       Impact factor: 4.736

7.  Hormonal control of glycogenolysis in parenchymal liver cells by Kupffer and endothelial liver cells.

Authors:  E Casteleijn; J Kuiper; H C van Rooij; J A Kamps; J F Koster; T J van Berkel
Journal:  J Biol Chem       Date:  1988-02-25       Impact factor: 5.157

8.  Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats.

Authors:  C E Heyliger; A G Tahiliani; J H McNeill
Journal:  Science       Date:  1985-03-22       Impact factor: 47.728

9.  Control of glycogen synthase and phosphorylase in hepatocytes from diabetic rats. Effects of glucagon, vasopressin, and vanadate.

Authors:  J E Rodríguez-Gil; A M Gómez-Foix; J Ariño; J J Guinovart; F Bosch
Journal:  Diabetes       Date:  1989-06       Impact factor: 9.461

10.  Oral administration of vanadate to diabetic rats restores liver 6-phosphofructo-2-kinase content and mRNA.

Authors:  M Miralpeix; E Carballo; R Bartrons; K Crepin; L Hue; G G Rousseau
Journal:  Diabetologia       Date:  1992-03       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.